SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Rep

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PK

LXEO

Related stories